Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MicroPort NeuroScientificHKSE:02172 -1.37%93 EV-to-FCF is 23.13 as of Aug. 11, 2026, which is 10% below its 10-year median of 25.75. GuruFocus rates HKSE:02172 with a GF Score™ of 93/100 and a GF Value™ of HK$13.19 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 412 Medical Devices & Instruments companies, MicroPort NeuroScientific ranks better than 52.43% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, MicroPort NeuroScientific's Enterprise Value is HK$3,949.8 Mil.
MicroPort NeuroScientific's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$170.7 Mil. Therefore, MicroPort NeuroScientific's EV-to-FCF for today is 23.13.
The historical rank and industry rank for MicroPort NeuroScientific's EV-to-FCF or its related term are showing as below:
HKSE:02172'
s EV-to-FCF Range Over the Past 10 Years
Min: -95.29 Med: 25.75 Max: 119.33
Current: 23.13
During the past 7 years, the highest EV-to-FCF of MicroPort NeuroScientific was 119.33. The lowest was -95.29. And the median was 25.75.
HKSE:02172's EV-to-FCF is ranked better than 52.43% of 412
companies
in the Medical Devices & Instruments industry
Industry Median: 24.855
vs HKSE:02172: 23.13
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MicroPort NeuroScientific's PE Ratio (TTM) for today is calculated as:
MicroPort NeuroScientific's share price for today is HK$9.005.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. MicroPort NeuroScientific's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.352.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
MicroPort NeuroScientific EV-to-FCF Related Terms
MicroPort NeuroScientific EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, MicroPort NeuroScientific's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MicroPort NeuroScientific EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MicroPort NeuroScientific's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where MicroPort NeuroScientific's EV-to-FCF falls into.
MicroPort NeuroScientific's current Enterprise Value is HK$3,949.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. MicroPort NeuroScientific's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$170.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MicroPort NeuroScientific (HKSE:02172) has a EV-to-FCF of 23.13 as of Aug. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on MicroPort NeuroScientific and its competitors. This is 10% below median its historical median of 25.75. According to the industry distribution chart, MicroPort NeuroScientific ranks #196 out of 412 companies in the Medical Devices & Instruments industry, placing it in the top 47.6%.
Is MicroPort NeuroScientific's EV-to-FCF too high?
MicroPort NeuroScientific's current EV-to-FCF of 23.13 is 10% below median its 10-year median of 25.75. The Medical Devices & Instruments industry median EV-to-FCF is 24.86. MicroPort NeuroScientific's value of 23.13 is 6.9% below this industry median. Based on the distribution chart, MicroPort NeuroScientific ranks #196 out of 412 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, MicroPort NeuroScientific has a GF Score™ of 93/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MicroPort NeuroScientific's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MicroPort NeuroScientific ranks #196 out of 412 companies for EV-to-FCF. This puts MicroPort NeuroScientific in the upper half of its industry. The industry median EV-to-FCF is 24.86. MicroPort NeuroScientific's value of 23.13 is 6.9% below this benchmark. While the company's 10-year median is 25.75 vs. the industry median of 24.86, MicroPort NeuroScientific has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 24.86, based on 412 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MicroPort NeuroScientific's current EV-to-FCF of 23.13 is 6.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on MicroPort NeuroScientific and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 24.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MicroPort NeuroScientific's current EV-to-FCF is 23.13, which is 10% below median its own 10-year median of 25.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MicroPort NeuroScientific stock overvalued right now?
Based on GuruFocus' analysis, MicroPort NeuroScientific (HKSE:02172) is currently considered Possible Value Trap. The stock's GF Value™ is HK$13.19, compared to a current price of HK$9.01 — trading 31.7% below its estimated fair value. The current EV-to-FCF is 23.13, which is 10% below median its 10-year median of 25.75 and 6.9% below the Medical Devices & Instruments industry median of 24.86. MicroPort NeuroScientific's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For MicroPort NeuroScientific (HKSE:02172), the current EV-to-FCF is 23.13 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MicroPort NeuroScientific (HKSE:02172) Overvalued in 2026?
Based on GuruFocus' analysis, MicroPort NeuroScientific stock appears to be undervalued.
The current stock price of HK$9.01 is trading 31.7% below its estimated GF Value™ of HK$13.19.
GuruFocus considers MicroPort NeuroScientific to be Possible Value Trap.
Key valuation signals for HKSE:02172:
EV-to-FCF: 23.13 (10% below median its 10-year median of 25.75)
GF Value™: HK$13.19 vs. price of HK$9.01 (31.7% below fair value)
Industry Position: 6.9% below the Medical Devices & Instruments median (#196 of 412)
No single metric tells the full story. See the HKSE:02172 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MicroPort NeuroScientific Corp is in the neuro-interventional medical device industry, dedicated to providing solutions for physicians and patients. The company boasts a comprehensive portfolio of approved therapeutic products covering all of three main areas of neurovascular disease, namely hemorrhagic stroke, cerebral atherosclerotic stenosis, and acute ischemic stroke. The company generates almost all of its revenue from the sale of medical devices. Geographically, the company generates the majority of its revenue from the PRC region, and also has operations in Israel.
93GF Score
Get the complete analysis for HKSE:02172
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02172 has been successfully added to your 
